1. Personalised Patient Diagnosis and Prognosis in Prostate Cancer: What Are the Future Perspectives? 
Luis Martínez-Piñeiro 
European Urology Supplements 
Volume 9, Issue 11, Pages (December 2010)
DOI: /j.eursup
Copyright © 2010 European Association of Urology Terms and Conditions

2. Fig. 1
Relationship between prostate cancer gene 3 (PCA3) score and prostate tumour volume assessed after radical prostatectomy. Reproduced with permission from Nakanishi et al [21].
European Urology Supplements 2010 9, DOI: ( /j.eursup )
Copyright © 2010 European Association of Urology Terms and Conditions

3. Fig. 2
Receiver operator curves for predicting extracapsular extension by preoperative serum prostate-specific antigen (PSA), prostate cancer gene 3 (PCA3) score, and biopsy Gleason score (bGS). Reproduced with permission from Whitman et al [22].
LR = logistic regression; AUC = area under the curve.
European Urology Supplements 2010 9, DOI: ( /j.eursup )
Copyright © 2010 European Association of Urology Terms and Conditions

4. Fig. 3
Development of gene fusions in prostate cancer that occur through translocation (TMPRSS2:ETV1) or chromosomal deletion (TMPRSS2:ERG). Reproduced with permission from Tomlins et al [25].
European Urology Supplements 2010 9, DOI: ( /j.eursup )
Copyright © 2010 European Association of Urology Terms and Conditions

5. Fig. 4
Kaplan-Meier estimates of probabilities of overall survival of castration-resistant prostate cancer patients with favourable (<5) and unfavourable (≥5) circulating tumour cells (CTCs). Reproduced with permission from de Bono et al [32].
European Urology Supplements 2010 9, DOI: ( /j.eursup )
Copyright © 2010 European Association of Urology Terms and Conditions